<DOC>
	<DOCNO>NCT01004861</DOCNO>
	<brief_summary>PLX3397 selective inhibitor Fms , Kit , oncogenic Flt3 activity . The primary objective study evaluate safety pharmacokinetics orally administer PLX3397 patient advance , incurable , solid tumor target kinase link disease pathophysiology . The secondary objective measure pharmacodynamic activity PLX3397 via blood , plasma urine biomarkers Fms activity .</brief_summary>
	<brief_title>Safety Study PLX108-01 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Age 18 old Solid tumor refractory standard therapy For Extension cohort , patient must measurable disease RECIST criterion meet follow diseasespecific criterion : For advanced recurrent mucoepidermal carcinoma ( MEC ) salivary gland , patient must candidate curative surgery radiotherapy . For pigmented villonodular synovitis ( PVNS ) , patient must histologically confirm diagnosis inoperable progressive relapsing PVNS , resectable tumor request mutilate surgery , well demonstrate progressive disease last 12 month . For gastrointestinal stromal tumor ( GIST ) , patient must fail previous therapy imatinib sunitinib . Patients know PDGFR mutation exclude , mutation testing require study entry . For anaplastic thyroid cancer ( ATC ) , patient must histologically cytologically diagnose advanced ATC . For metastatic solid tumor document malignant pleural and/or peritoneal effusion , patient must receive specific therapy effusion indwell drain . ECOG performance status 0 1 Life expectancy &gt; = 3 month Adequate hepatic , renal , bone marrow function Specific anticancer therapy within 3 week study start Uncontrolled intercurrent illness Refractory nausea vomiting , malabsorption Mean QTc &gt; = 450 msec ( male ) QTc &gt; = 470 msec ( female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PVNS</keyword>
</DOC>